Search results
Morning Brew: Tesla's CEO Pay Package Approved, MicroStrategy Up
Guru Focus· 16 hours agoS&P futures vs fair value: -28.00. Nasdaq futures vs fair value: -58.00.The S&P 500 futures are down...
Moderna director Afeyan sells over $30 million in company stock By Investing.com
Investing.com· 3 days agoThe transactions, which took place on June 11, 2024, resulted in the sale of Moderna stock worth...
Xencor shares target cut by BMO on plamotamab rights By Investing.com
Investing.com· 18 hours agoOn Friday, BMO (TSX:BMO) Capital adjusted its outlook for Xencor, Inc. (NASDAQ: NASDAQ:XNCR) shares,...
Moderna (MRNA) COVID-Flu Combo Jab Meets Late-Stage Study Goal
Zacks via Yahoo Finance· 4 days agoData from a late-stage study shows that Moderna's (MRNA) experimental COVID-19-influenza combination...
Questor: Investors are undervaluing this London company’s pubs and hotels
The Telegraph via Yahoo Finance· 5 days agoWe are hopefully not tempting providence by taking a fresh look at Fuller Smith & Turner ahead of...
Health Care Roundup: Market Talk
The Wall Street Journal· 3 days agoThe brokerage initiates coverage of the stock with an add rating and a target price of THB58.00. In addition to the younger generation and females, males...
Daily Brief: Apple’s AI strategy
Quartz· 4 days ago“Apple Intelligence” is a new collection of AI features that is focused on personal products, and privacy is a huge goal of executives.
Market Today: Broadcom Soars, Ford Adjusts EV Strategy Amidst Sl
Guru Focus· 1 day agoMarket OverviewThe S&P 500 (+0.2%) and Nasdaq Composite (+0.3%) added to their record closing highs...
CNBC Daily Open: Apple upgrades Siri with AI
CNBC· 4 days agoThe S&P 500 and the Nasdaq Composite inched to record highs ahead of the Federal Reserve's interest rate decision. Shares of Apple fell 1.9% after the iPhone maker delivered its long-awaited ...
Sarepta shares hold steady as competitor drug fails trial By Investing.com
Investing.com· 2 days agoOn Thursday, BMO Capital maintained a positive outlook on Sarepta Therapeutics (NASDAQ:SRPT),...